Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (51-60 of 154) with videos related to

Pageof 16
Sort By:
Oncology Reports|May 26, 2016
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancerGiovanni Luca Gravina, Francesco Marampon, Patrizia Sanità, et al.
European Journal of Pharmacology|December 11, 2017
Distinctive binding properties of the negative allosteric modulator, [<sup>3</sup>H]SB269,652, at recombinant dopamine D<sub>3</sub> receptorsIrene Fasciani, Ilaria Pietrantoni, Mario Rossi, et al.
Neuroscience|March 7, 2020
A New Threat to Dopamine Neurons: The Downside of Artificial LightIrene Fasciani, Francesco Petragnano, Gabriella Aloisi, et al.
Journal of Neurological Surgery. Part A, Central European Neurosurgery|July 3, 2024
The Impact of the COVID-19 Pandemic and Lockdown on the Outcome of GlioblastomaDaniele Armocida, Luca D'Angelo, Raffaella De Pietro, et al.
Cancer Drug Resistance (Alhambra, Calif.)|December 22, 2025
Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcomaSilvia Codenotti, Francesco Marampon, Francesca Megiorni, et al.
The Prostate|March 25, 2010
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumorsGiovanni Luca Gravina, Francesco Marampon, Mario Di Staso, et al.
Archives of Biochemistry and Biophysics|December 16, 2022
Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell linesMichela Rossi, Viviana De Martino, Laura Di Giuseppe, et al.
European Journal of Histochemistry : EJH|July 25, 2017
The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studyRoberta Sferra, Simona Pompili, Claudio Festuccia, et al.
Experimental Cell Research|June 2, 2006
HDAC inhibition is associated to valproic acid induction of early megakaryocytic markersFrancesca Vulcano, Carmela Ciccarelli, Gianfranco Mattia, et al.
Current Pharmaceutical Design|November 15, 2019
Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's DiseaseBiancamaria Longoni, Irene Fasciani, Shivakumar Kolachalam, et al.
Pageof 16

Showing results (51-60 of 154) with videos related to

Sort By:
Pageof 16
Oncology Reports|May 26, 2016
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancerGiovanni Luca Gravina, Francesco Marampon, Patrizia Sanità, et al.
European Journal of Pharmacology|December 11, 2017
Distinctive binding properties of the negative allosteric modulator, [<sup>3</sup>H]SB269,652, at recombinant dopamine D<sub>3</sub> receptorsIrene Fasciani, Ilaria Pietrantoni, Mario Rossi, et al.
Neuroscience|March 7, 2020
A New Threat to Dopamine Neurons: The Downside of Artificial LightIrene Fasciani, Francesco Petragnano, Gabriella Aloisi, et al.
Journal of Neurological Surgery. Part A, Central European Neurosurgery|July 3, 2024
The Impact of the COVID-19 Pandemic and Lockdown on the Outcome of GlioblastomaDaniele Armocida, Luca D'Angelo, Raffaella De Pietro, et al.
Cancer Drug Resistance (Alhambra, Calif.)|December 22, 2025
Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcomaSilvia Codenotti, Francesco Marampon, Francesca Megiorni, et al.
The Prostate|March 25, 2010
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumorsGiovanni Luca Gravina, Francesco Marampon, Mario Di Staso, et al.
Archives of Biochemistry and Biophysics|December 16, 2022
Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell linesMichela Rossi, Viviana De Martino, Laura Di Giuseppe, et al.
European Journal of Histochemistry : EJH|July 25, 2017
The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studyRoberta Sferra, Simona Pompili, Claudio Festuccia, et al.
Experimental Cell Research|June 2, 2006
HDAC inhibition is associated to valproic acid induction of early megakaryocytic markersFrancesca Vulcano, Carmela Ciccarelli, Gianfranco Mattia, et al.
Current Pharmaceutical Design|November 15, 2019
Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's DiseaseBiancamaria Longoni, Irene Fasciani, Shivakumar Kolachalam, et al.
Pageof 16